Dr. Payne's presentation, “Advanced Technology and Service Solutions for Today's Biologics Challenges” will take place at Clare College on Thursday, September 29, 2011 from 11:15 am to 11:45 am.
Dr. Payne will discuss how candidate selection programs can be used to balance risk and innovation against potential, and cost of further development. He will contend that the selection of development partners with advantaged technologies and broad product development capabilities may better ensure internal resources are available for development from gene to clinic. Topics will include: the ability to move from cDNA to gram quantities of protein from a high expressing cell pool in a commercial production media in 12 weeks with Catalent's GPEx® system provides discovery scientists a powerful tool to screen multiple constructs in a short period of time and increases the potential of selecting an optimal target;
why selecting technologies that provide higher expression levels at cell pool or clonal selection stage increases the probability of higher efficiencies being achieved later through upstream/downstream development activities and ultimately mean the difference between reaching the next milestone and being advantaged all the way to market; and
why it is important for discovery teams to have access to partners with a broad range of capabilities beyond the mainstay sterile delivery mechanisms; for example, to rapidly contrast proteins intended for delivery via the inhaled route of administration.
For more information on this event, please click here.
Catalent Expert to Present Advanced Technology Solutions for Today's Biologics Challenges
Kent Payne, Ph.D., Vice President and General Manager, Development and Clinical Services, at Catalent Pharma Solutions is to present at the One Nucleus Life Science Leadership - Healthcare Technologies event in Cambridge, UK.
Sep 28th, 2011
Companies in this article
